Pembrolizumab is a potential new treatment option for stage IB-IIIA non-small cell lung cancer after complete resection, according to researchers.
Researchers sought to determine if self-reported lung-related comorbidities was an indicator of poor outcomes on lung cancer screening.
The approvals were based on data from the LIBRETTO-001 trial.
Many patients with advanced non-small cell lung cancer do not survive long enough to receive second-line therapy, a real-world study suggests.
Adjuvant osimertinib continues to demonstrate a disease-free survival benefit vs placebo in resected, stage IB-IIIA, EGFR-mutated non-small cell lung cancer.